Follistatin-344: Isoforms, Ligand Sequestration and What the Certificate Must Show

The primary translation product of the human FST gene runs to 344 residues, and Follistatin-344 is exactly that: a secreted, activin-binding glycoprotein of about 37.8 kDa which neutralises a number of TGF-β superfamily ligands — activin A and myostatin (GDF-8) among them — by enveloping them and denying access to their receptors. In the everyday sense of the word it is no peptide: 344 amino acids make a folded, disulfide-rich, multi-domain protein produced by recombinant expression, and it behaves in the laboratory as such.

Our Follistatin-344 is a recombinant protein supplied lyophilized in a 1 mg vial, listed in the IGF and muscle peptides range. It is supplied for laboratory research only.

Defining Follistatin-344

The figure in the name counts residues, and it tells you which isoform the vial holds. Alternative splicing of the FST gene yields two principal products. FS-344 is what the longer transcript translates to; strip away its N-terminal signal sequence and you have the 315-residue FS-315, the species that predominates in serum and bears an acidic C-terminal tail. The alternatively spliced FS-288 has no such tail, binds heparan sulfate proteoglycans, and consequently remains attached to cell surfaces and basement membrane instead of circulating.

This difference has real consequences. Distribution behaviour within the same protein family varies sharply by isoform, so any study drawing on results from several sources has to establish the isoform first. The catalogue identifiers here are CAS 80449-31-6 and a molecular weight of approximately 37,800 Da.

Origin and structure

First isolated from ovarian follicular fluid in 1987, the protein was recognised through its capacity to suppress pituitary secretion of follicle-stimulating hormone — which is how it got its name. Only later did its function as a broad trap for TGF-β ligands become clear, and the muscle literature came later still.

The architecture comprises an N-terminal domain followed by three cysteine-rich follistatin domains, each with EGF-like and Kazal-like motifs. Function resides in a complex rather than a monomer: two follistatin molecules close around one activin dimer, concealing nearly all of the ligand's type I and type II receptor-binding surfaces. That interaction has picomolar affinity for activin A, which is why the protein works as a genuine neutralising trap instead of a competitive modulator.

In its native form follistatin is glycosylated. Recombinant material from bacterial expression is not, and glycosylation influences solubility, clearance and at times apparent potency. The expression system is therefore a specification to verify on the certificate, not a footnote.

The proposed mechanism

Sequestration of ligands, rather than antagonism at a receptor, is the mechanism. Follistatin captures free activin A, myostatin (GDF-8), GDF-11 and certain bone morphogenetic proteins, keeping them from reaching the type II activin receptors ActRIIA and ActRIIB on the cell surface. The consequence downstream is less receptor-driven phosphorylation of SMAD2/3 — in skeletal muscle, the signalling limb associated with transcriptional restraint of growth — and muscle models report a shift in favour of Akt/mTOR signalling.

Selectivity is where the mechanistic caution lies. The binding profile is deliberately broad: activin A is bound most tightly of all, and activin signalling underpins reproductive endocrinology, inflammation and haematopoiesis alongside muscle. Using follistatin to probe the myostatin axis is therefore not a pathway-specific intervention, and any interpretation has to allow for the activin arm. That is the main mechanistic distinction between follistatin and a receptor-decoy strategy such as ACE-031, and between follistatin and a ligand-specific tool such as the GDF-8 / myostatin propeptide.

Published pharmacokinetic work puts circulating persistence at only a few hours, one reason the most-cited whole-animal studies have used gene delivery in place of protein administration.

What has been studied

Skeletal muscle and myostatin pathway models

Genetics produced the best-known results. Mice engineered to overexpress follistatin in skeletal muscle gained substantially more muscle mass than myostatin-null animals did — evidence that follistatin acts on targets beyond myostatin. Crosses of follistatin-null and myostatin-null animals were used to nail that point down.

Gene delivery studies

Adeno-associated virus gene-transfer work uses the FS-344 isoform specifically. Early-phase clinical studies delivering AAV1-FS344 into muscle in Becker muscular dystrophy and in sporadic inclusion body myositis appeared during the 2010s, with endpoints based on muscle biopsy and walking distance. They delivered the gene rather than recombinant protein and were small early-phase investigations, so they say nothing about administering the protein.

Reproductive and endocrine biology

The oldest and still the largest literature covers follistatin's control of FSH secretion and its part in ovarian follicular development, activin binding being the mechanism of interest. A good deal of assay work in this field employs recombinant follistatin as a neutralising reagent.

Fibrosis and inflammation models

Since activin A contributes to fibrotic and inflammatory signalling, follistatin has served as a pathway-blocking tool in rodent models of liver, lung and kidney fibrosis. Those findings remain preclinical.

Presentations available

For a 37.8 kDa protein used at nanomolar working concentrations, 1 mg is a large molar quantity, so most laboratories aliquot the whole vial at first reconstitution rather than coming back to it. Sourcing considerations appear in our Follistatin-344 buying guide.

Reconstitution and storage at the bench

Treat follistatin as the recombinant protein it is, with gentler technique than a short synthetic peptide would need. Add sterile or bacteriostatic water slowly down the wall of the vial and leave it to stand instead of vortexing; a multi-domain protein held together by disulfides is far more vulnerable to shear denaturation than a 24-mer. If the solution looks cloudy afterwards, that is aggregation — a signal to stop rather than to shake harder.

The arithmetic is simple enough — 1 mg brought to 1 mL gives 1 mg/mL, so 0.1 mL holds 100 mcg — though working concentrations usually sit several dilutions below. At those levels the main route of loss is adsorption to plastic, which is why dilute stocks routinely include a carrier protein such as 0.1% bovine serum albumin. Our reconstitution guide has the method in detail.

Keep lyophilized vials at −20 °C, shielded from light and moisture. Use reconstituted material promptly at 2–8 °C, or aliquot it and hold it at −20 °C or colder; for proteins in this class nothing destroys activity more reliably than repeated freezing and thawing. Storage guidance for peptides covers the broader picture.

Purity, the COA and how to read it

With a protein of this size, an HPLC purity figure falls short. The informative entries are the SDS-PAGE lane, which under reducing conditions should give a single band at the expected mass and which exposes aggregates and clipped species a reversed-phase trace can overlook; the expression system, because bacterial expression produces non-glycosylated protein where mammalian or insect systems do not; and the endotoxin figure, which matters for anything destined for cell culture. Most meaningful of all is a bioactivity statement — usually neutralisation of activin A in a reporter assay — since a protein of the right size but the wrong fold will pass a purity test and then fail the experiment. The general anatomy of these documents is set out in our guide to reading a certificate of analysis.

Regulatory position

No jurisdiction has authorised Follistatin-344 for marketing as a medicine. The gene-therapy construct examined in early-phase muscular dystrophy trials is an investigational product and is not equivalent to recombinant protein sold as a reagent. Agents acting on the myostatin pathway are banned in sport under anti-doping rules.

Related molecules and further reading

Along the same pathway, ACE-031 represents the receptor-decoy route and the GDF-8 / myostatin propeptide the ligand-specific one; since the three intervene at different points, they are not interchangeable. For wider orientation, see our peptides for muscle growth research overview.